Cancer Tumor Profiling Market Report 2025 (Global Edition)

Global Cancer Tumor Profiling Market Report 2025 Market Size Split by Technology (Next-generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (...

Cancer Tumor Profiling Market Report Description

We have various report editions of Cancer Tumor Profiling Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Cancer Tumor Profiling Market Insights Video

Competitive Landscape of the Cancer Tumor Profiling Market

The competitive landscape of the Cancer Tumor Profiling market is characterized by a diverse range of players competing to gain market share through product innovation, strategic partnerships, and aggressive marketing efforts. Key players in the market include established electronics manufacturers, specialized Cancer Tumor Profiling companies, and emerging start-ups aiming to disrupt the market with innovative solutions.

May 2022: QIAGEN launched the therascreen EGFR Plus RGQ PCR Kit, an innovative in-vitro diagnostic test designed for sensitive EGFR mutation analysis. This test empowers oncologists to improve the treatment guidance for non-small cell lung cancer (NSCLC) patients.

(Source:https://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2022/QIAGEN-launches-therascreen-EGFR-Plus-RGQ-PCR-Kit-featuring-C797S-detection-to-help-guide-non-small-cell-lung-cancer-NSCLC-treatment/default.aspx )

January 2022: Illumina formed a partnership with Agendia to enhance next-generation sequencing for decentralized oncology testing. This collaboration is expected to provide improved insights for breast cancer patients worldwide.

(Source:https://www.illumina.com/company/about-us/corporate-social-responsibility/news-feed.html?mid=360911&pgno=17&fdpgno=1 )

Top Companies Market Share in Cancer Tumor Profiling Industry: (In no particular order of Rank)

• Illumina
• Inc.
• QIAGEN
• NeoGenomics Laboratories
• Inc.
• HTG Molecular Diagnostics
• Inc.
• Genomic Health Inc.
• Caris Life Sciences
• Helomics Corporation
• NanoString Technologies
• Inc.
• Sysmex Corporation
• Ribomed Biotechnologies
• Inc.
• Guardant Health
• Inc.
• Foundation Medicine
• Roche Diagnostics
• GenScript Biotech Corporation
• Tempus Labs
• Boreal Genomics Inc
• Perthera
• Agenda
• Omniseq
• Histogene X
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Cancer Tumor Profiling Market

Which Region Dominates the Cancer Tumor Profiling Market in 2024?

According to Cognitive Market Research, North America dominated the market in 2024. It accounted for around 40% of the region's advanced healthcare infrastructure, significant investments in research and development, and a high prevalence of cancer cases. Additionally, North America boasts a robust network of pharmaceutical and biotechnology companies, along with academic and research institutions, which collectively drive innovation in cancer tumor profiling technologies. Furthermore, favorable government initiatives and policies aimed at promoting precision medicine and personalized cancer treatment have also contributed to the dominance of North America in the global cancer tumor profiling market. These factors have fostered the adoption of advanced diagnostic and therapeutic solutions, thereby propelling market growth in the region.

Which Region is Expanding at the Fastest CAGR?

Asia Pacific stands out as the fastest-growing region in the Cancer Tumor Profiling market due to the rising incidence of cancer across the Asia Pacific region is driving the demand for advanced diagnostic and treatment methods, including tumor profiling. Moreover, increasing awareness about the importance of early detection and personalized treatment options among both healthcare professionals and patients is further fueling the adoption of cancer tumor profiling technologies.

The current report Scope analyzes Cancer Tumor Profiling Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Cancer Tumor Profiling

According to Cognitive Market Research, the global Cancer Tumor Profiling market size was estimated at USD 9915.2 Million, out of which North America held the major market of more than 40% of the global revenue with a market size of USD 3966.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.8% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Cancer Tumor Profiling market with a market size of USD 3129.24 million in 2024 and is projected to grow at a CAGR of 11.6% during the forecast period. The demand is amplified by the nation's advanced healthcare infrastructure, substantial investment in research and development, and a strong focus on precision medicine initiatives. Additionally, the prevalence of cancer cases in the US and the growing awareness of the benefits of tumor profiling for personalized treatment strategies further drive market growth.
• The Canada Cancer Tumor Profiling market had a market share of USD 475.93 million in 2024 and is projected to grow at a CAGR of 12.6% during the forecast period.
• The Mexico Cancer Tumor Profiling market is projected to witness growth at a CAGR of 12.3% during the forecast period, with a market size of USD 360.91 million in 2024.

Europe Cancer Tumor Profiling

According to Cognitive Market Research, the global Cancer Tumor Profiling market size was estimated at USD 9915.2 Million, out of which Europe held the market of more than 30% of the global revenue with a market size of USD 2974.56 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.1% from 2024 to 2031.

• The United Kingdom Cancer Tumor Profiling market had a market share of USD 499.73 million in 2024 and is projected to grow at a CAGR of 12.9% during the forecast period. The growth of the United Kingdom Cancer Tumor Profiling market is driven by the country's strong emphasis on research and innovation in precision medicine, coupled with robust healthcare infrastructure and increasing awareness about personalized cancer treatment strategies.
• The France Cancer Tumor Profiling market is projected to witness growth at a CAGR of 11.3% during the forecast period, with a market size of USD 273.66 million in 2024.
• According to Cognitive Market Research, the German cancer Tumor Profiling market size was valued at USD 588.96 million in 2024 and is projected to grow at a CAGR of 12.3% during the forecast period.
• The Italy Cancer Tumor Profiling market is projected to witness growth at a CAGR of 11.5% during the forecast period, with a market size of USD 255.81 million in 2024.
• The Russia Cancer Tumor Profiling market is projected to witness growth at a CAGR of 11.1% during the forecast period, with a market size of USD 461.06 million in 2024.
• The Spain Cancer Tumor Profiling market is projected to witness growth at a CAGR of 11.2% during the forecast period with a market size of USD 243.91 million in 2024
• The Luxembourg Cancer Tumor Profiling market is projected to witness growth at a CAGR of 12.2% during the forecast period, with a market size of USD 92.21 million in 2024.
• The Portugal Cancer Tumor Profiling market is projected to witness growth at a CAGR of 11.9% during the forecast period, with a market size of USD 62.47 million in 2024.
• The Greece Cancer Tumor Profiling market is projected to witness growth at a CAGR of 12.4% during the forecast period, with a market size of USD 35.69 million in 2024.
• Rest of Europe's Cancer Tumor Profiling market is projected to witness growth at a CAGR of 10.8% during the forecast period, with a market size of USD 461.06 million in 2024.

Asia Pacific Cancer Tumor Profiling

According to Cognitive Market Research, the global Cancer Tumor Profiling market size was estimated at USD 9915.2 Million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 2280.50 million in 2024 and will grow at a compound annual growth rate (CAGR) of 15.6% from 2024 to 2031.

• According to Cognitive Market Research, the China Cancer Tumor Profiling market size was valued at USD 1026.22 million in 2024 and is projected to grow at a CAGR of 15.1% during the forecast period. Cancer Tumor Profiling sales surged in China due to the country's growing healthcare infrastructure, expanding biotechnology and pharmaceutical sectors, and increasing investments in precision medicine research. Additionally, the rising prevalence of cancer cases in China and the government's initiatives to promote early detection and personalized treatment strategies contribute to the surge in Cancer Tumor Profiling sales in the country.
• The Japan Cancer Tumor Profiling market is projected to witness growth at a CAGR of 14.1% during the forecast period, with a market size of USD 314.71 million in 2024.
• The India Cancer Tumor Profiling market had a market share of USD 273.66 million in 2024 and is projected to grow at a CAGR of 17.4% during the forecast period.
• The South Korea Cancer Tumor Profiling market is projected to witness growth at a CAGR of 14.7% during the forecast period, with a market size of USD 228.04 million in 2024.
• The Australia Cancer Tumor Profiling market is projected to witness growth at a CAGR of 15.3% during the forecast period, with a market size of USD 118.59 million in 2024.
• The South East Asia Cancer Tumor Profiling market is projected to witness growth at a CAGR of 16.6% during the forecast period, with a market size of USD 157.35 million in 2024.
• The Rest of Asia Pacific Cancer Tumor Profiling market is projected to witness growth at a CAGR of 15.4% during the forecast period, with a market size of USD 161.92 million in 2024.

South America Cancer Tumor Profiling

According to Cognitive Market Research, the global Cancer Tumor Profiling market size was estimated at USD 9915.2 Million, out of which the Latin America market of more than 5% of the global revenue with a market size of USD 495.76 million in 2024. It will grow at a compound annual growth rate (CAGR) of 13.0% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Cancer Tumor Profiling market size was valued at USD 212.19 million in 2024 and is projected to grow at a CAGR of 13.6% during the forecast period. Cancer Tumor Profiling sales flourish in Brazil due to the country's large population, increasing healthcare investments, and rising incidence of cancer cases.
• Argentina's Cancer Tumor Profiling market had a market share of USD 83.29 million in 2024 and is projected to grow at a CAGR of 13.9% during the forecast period.
• Colombia's Cancer Tumor Profiling market is projected to witness growth at a CAGR of 12.8% during the forecast period, with a market size of USD 44.12 million in 2024.
• Peru Cancer Tumor Profiling market is projected to witness growth at a CAGR of 13.2% during the forecast period, with a market size of USD 40.45 million in 2024.
• Chile's Cancer Tumor Profiling market is projected to witness growth at a CAGR of 13.3% during the forecast period, with a market size of USD 35.69 million in 2024.
• The Rest of Latin America's Cancer Tumor Profiling market is projected to witness growth at a CAGR of 12.1% during the forecast period, with a market size of USD 79.82 million in 2024.

Middle East and Africa Cancer Tumor Profiling

According to Cognitive Market Research, the global Cancer Tumor Profiling market size was estimated at USD 9915.2 Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 198.30 million in 2024 and will grow at a compound annual growth rate (CAGR) of 13.3% from 2024 to 2031.

• The GCC Countries Cancer Tumor Profiling market is projected to witness growth at a CAGR of 14.1% during the forecast period, with a market size of USD 84.87 million in 2024. The growth of the GCC Countries' Cancer Tumor Profiling market is fueled by the region's increasing healthcare investments, rising prevalence of cancer, and growing adoption of advanced medical technologies.
• The Egypt Cancer Tumor Profiling market is projected to witness growth at a CAGR of 13.6% during the forecast period, with a market size of USD 20.82 million in 2024.
• The South Africa Cancer Tumor Profiling market is projected to witness growth at a CAGR of 14.3% during the forecast period, with a market size of USD 31.33 million in 2024.
• The Turkey Cancer Tumor Profiling market is projected to witness growth at a CAGR of 12.8% during the forecast period, with a market size of USD 17.05 million in 2024.
• The Nigeria Cancer Tumor Profiling market is projected to witness growth at a CAGR of 12.4% during the forecast period, with a market size of USD 20.82 million in 2024.
• The Rest of the MEA Cancer Tumor Profiling market is projected to witness growth at a CAGR of 12.3% during the forecast period, with a market size of USD 23.40 million in 2024.

Cancer Tumor Profiling Market Analysis

How are Segments Performing in the Global Cancer Tumor Profiling Market?

Cancer Tumor Profiling Market Technology Segment Analysis

According to Cognitive Market Research, Next-generation Sequencing (NGS) emerges as the dominating segment. NGS offers high throughput sequencing capabilities, enabling the comprehensive analysis of genetic alterations in tumors. Its ability to simultaneously detect mutations, gene expression changes, and structural variations makes it a preferred choice for oncologists and researchers. Additionally, advancements in NGS technologies have led to increased accuracy, reduced turnaround times, and lower costs, further solidifying its dominance in the market.

Polymerase Chain Reaction (PCR) stands out as the fastest-growing segment in the cancer tumor profiling market. PCR techniques, including digital PCR and real-time PCR, provide sensitive and specific detection of genetic mutations and alterations in cancer cells. The growing demand for PCR-based assays for targeted mutation profiling, minimal residual disease monitoring, and companion diagnostics development is driving the rapid expansion of this segment. Moreover, ongoing technological advancements in PCR platforms and assay designs are enhancing their utility and driving adoption across research and clinical settings, thereby fueling the growth of the PCR segment in the cancer tumor profiling market.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Cancer Tumor Profiling Industry. Request a Free Sample PDF!

Cancer Tumor Profiling Market Technique Segment Analysis

According to Cognitive Market Research, Genomics emerges as the dominating segment. Genomics involves the comprehensive study of an organism's complete set of DNA, including its genes and their functions. In cancer tumor profiling, genomic techniques such as Next-generation Sequencing (NGS) play a pivotal role in identifying genetic alterations, mutations, and gene expression patterns associated with cancer development and progression. The ability of genomic profiling to provide insights into the underlying molecular mechanisms of cancer and guide personalized treatment strategies makes it a cornerstone in oncology research and clinical practice, thus solidifying its dominance in the market.

Metabolomics stands out as the fastest-growing segment in the Cancer Tumor Profiling Market. Metabolomics focuses on the study of small molecules known as metabolites, which are involved in cellular processes and pathways. Metabolomic profiling of cancer tumors offers valuable insights into metabolic dysregulation associated with tumorigenesis and provides potential biomarkers for early detection, prognosis, and treatment response prediction. The growing recognition of the importance of metabolic reprogramming in cancer biology, coupled with advancements in analytical techniques such as mass spectrometry and nuclear magnetic resonance spectroscopy, is driving the rapid expansion of the metabolomics segment in the cancer tumor profiling market.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Cancer Tumor Profiling Application Segment Analysis

Application Segment Analysis

According to Cognitive Market Research, Personalized Medicine emerges as the dominating segment. Personalized medicine involves tailoring medical treatment to the individual characteristics of each patient, including their genetic makeup, lifestyle, and environmental factors. In cancer tumor profiling, personalized medicine utilizes genomic and molecular profiling techniques to identify specific genetic alterations and biomarkers associated with an individual's cancer, thereby enabling targeted therapies and precision oncology approaches. The increasing adoption of personalized medicine in oncology practice, driven by advancements in genomic technologies and the growing understanding of cancer heterogeneity, contributes to the dominance of this segment in the market.

Biomarker Discovery stands out as the fastest-growing segment in the Cancer Tumor Profiling Market. Biomarkers are measurable indicators of biological processes or disease states, and their discovery plays a crucial role in cancer research and clinical practice. Biomarker discovery techniques, such as genomic profiling, proteomics, and metabolomics, facilitate the identification of novel biomarkers associated with cancer diagnosis, prognosis, and treatment response. The growing demand for precision medicine approaches, and the development of companion diagnostics drive the rapid expansion of the biomarker discovery segment as researchers and healthcare providers seek to identify and validate biomarkers for improving patient outcomes in cancer care.

• Personalized Medicine
• Diagnostics
• Biomarker Discovery
• Prognostics
• Research Applications
• Others

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion